Rosales-Reynoso Mónica Alejandra, Arredondo-Valdez Abril Renee, Wence-Chávez Laura Ivonne, Barros-Núñez Patricio, Gallegos-Arreola Martha P, Flores-Martínez Silvia Esperanza, Sánchez-Corona Jose
1 División de Medicina Molecular, Centro de Investigación Biomédica de Occidente (CIBO), Centro Médico Nacional de Occidente (CMNO), Instituto Mexicano del Seguro Social (IMSS) , Guadalajara, México .
2 División de Genética, Centro de Investigación Biomédica de Occidente (CIBO), Centro Médico Nacional de Occidente (CMNO), Instituto Mexicano del Seguro Social (IMSS) , Guadalajara, México .
Genet Test Mol Biomarkers. 2016 Aug;20(8):438-44. doi: 10.1089/gtmb.2016.0026. Epub 2016 May 26.
AIM: The aim of this study was to investigate the association of the rs2240308 and rs1133683 polymorphisms in the AXIN2 gene with colorectal cancer (CRC) in Mexican patients. MATERIALS AND METHODS: Genomic DNAs from 201 CRC patients and 100 healthy blood donors were analyzed for AXIN2 gene polymorphisms by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methodology. Statistical associations were calculated using the odds ratio (OR) test. RESULTS: The genotype distribution of the rs1133683 polymorphism C > T showed a statistical difference between the two study groups (p = 0.0019). Moreover, OR analyses demonstrated that individuals with either the C/T or T/T genotype have a decreased risk for CRC compared with individuals with the C/C genotype (OR = 0.47, 95% confidence interval [CI] = 0.25-0.86, p = 0.0134 and OR = 0.24, 95% CI = 0.10-0.57, p = 0.005, respectively). This association was also evident in a stratified analysis based on tumor-node-metastasis (TNM) stage. For the rs2240308 polymorphism C > T, the OR analysis showed a significantly increased risk for carriers of the T/T genotype (OR = 2.64, 95% CI = 1.12-6.24, p = 0.0236) and this association was also evident in the stratified analysis by TNM stage. CONCLUSION: Our results indicate the possibility that variations in the AXIN2 gene may play a significant role in promoting or preventing CRC development.
Genet Test Mol Biomarkers. 2016-8
Asian Pac J Cancer Prev. 2021-8-1
Arch Iran Med. 2019-8-1
Cell Mol Biol (Noisy-le-grand). 2016-9-30
Med Oncol. 2010-11-11
Scand J Gastroenterol. 2011-4
Genet Mol Res. 2015-12-1
Signal Transduct Target Ther. 2021-8-30
Nat Rev Cancer. 2021-1
Biochem Med (Zagreb). 2020-10-15
BDJ Open. 2019-10-16
Br J Pharmacol. 2017-8-11